Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heo, Jung Yeon | - |
dc.contributor.author | Seo, Yu Bin | - |
dc.contributor.author | Jeong, Hye Won | - |
dc.contributor.author | Choi, Min Joo | - |
dc.contributor.author | Min, Kyung Hoon | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Lee, Jacob | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.contributor.author | Song, Joon Young | - |
dc.date.accessioned | 2022-03-14T02:42:07Z | - |
dc.date.available | 2022-03-14T02:42:07Z | - |
dc.date.created | 2021-12-24 | - |
dc.date.issued | 2020-11-17 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/138897 | - |
dc.description.abstract | Background: South Korea has been providing 10-valent pneumococcal conjugate vaccine/(PCV10)/13-valent pneumococcal conjugate vaccine (PCV13) to children and 23-valent pneumococcal polysaccharide vaccine (PPSV23) to older adults as part of a national immunization program. Methods: From September 2015 to August 2017, a prospective cohort study was conducted for adults aged >= 19 years with community-acquired pneumonia (CAP) at four university hospitals. All-cause and pneumococcal CAP incidence and mortality rates were evaluated on the basis of hospital catchment population. Serotype distribution of pneumococcal CAP was also evaluated. Results: Among 2669 patients with CAP, 252 cases (9.4%) were pneumococcal CAP cases. The annual incidences of all-cause and pneumococcal CAP were 194.3 cases and 18.3 cases respectively, per 100,000 persons. Serotyped Streptococcus pneumoniae was identified in 107 cases (42.5%) through culture or a serotype-specific urinary antigen detection assay. Pneumococcal CAP caused by the PCV13 and PPSV23 serotypes were 50 cases (46.7% of serotyped pneumococcal CAP and 19.8% of pneumococcal CAP), and 83 cases (77.6% of serotyped pneumococcal CAP and 32.9% of pneumococcal CAP), respectively. The most prevalent serotype was 3 (n = 21, 19.6% of serotyped pneumococcal CAP), followed by 19A (n = 10, 9.3% of serotyped pneumococcal CAP) and 11A (n = 10, 9.3% of serotyped pneumococcal CAP). Compared with non-pneumococcal CAP patients, pneumococcal CAP patients were more likely to have a higher CURB65 scores (P = 0.002). The overall 30-day mortality rate of pneumococcal CAP was higher than that of non-pneumococcal CAP (6.3% versus 5.6%; odds ratio [OR], 1.15; 95% confidence interval [CI], 0.67-1.96), but this trend was reversed in patients aged 65-74 years (4.2% versus 8.6%; OR, 0.47; 95% CI, 0.14-1.54). Conclusions: The disease burden of PCV13-serotype pneumococcal CAP remains significantly high in Korean adults, particularly among elderly people, even after a high uptake of pediatric PCVs. (C) 2020 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | POLYSACCHARIDE VACCINE | - |
dc.subject | ADULTS | - |
dc.subject | DISEASE | - |
dc.subject | BURDEN | - |
dc.subject | 13-VALENT | - |
dc.subject | ADMISSIONS | - |
dc.subject | EFFICACY | - |
dc.subject | IMPACT | - |
dc.title | Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Min, Kyung Hoon | - |
dc.contributor.affiliatedAuthor | Choi, Won Suk | - |
dc.contributor.affiliatedAuthor | Noh, Ji Yun | - |
dc.contributor.affiliatedAuthor | Cheong, Hee Jin | - |
dc.contributor.affiliatedAuthor | Kim, Woo Joo | - |
dc.contributor.affiliatedAuthor | Song, Joon Young | - |
dc.identifier.doi | 10.1016/j.vaccine.2020.10.046 | - |
dc.identifier.scopusid | 2-s2.0-85094140303 | - |
dc.identifier.wosid | 000588128100007 | - |
dc.identifier.bibliographicCitation | VACCINE, v.38, no.49, pp.7747 - 7755 | - |
dc.relation.isPartOf | VACCINE | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 38 | - |
dc.citation.number | 49 | - |
dc.citation.startPage | 7747 | - |
dc.citation.endPage | 7755 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | 13-VALENT | - |
dc.subject.keywordPlus | ADMISSIONS | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | BURDEN | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | POLYSACCHARIDE VACCINE | - |
dc.subject.keywordAuthor | Community-acquired pneumonia | - |
dc.subject.keywordAuthor | Epidemiology | - |
dc.subject.keywordAuthor | Incidence | - |
dc.subject.keywordAuthor | Mortality | - |
dc.subject.keywordAuthor | Pneumococcus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.